http://www.paxilbirthdefectlaw.com/ Losing a costly legal battle with the US federal government, SB Pharmaco Inc. and its parent holding firm GlaxoSmithKline (GSK) paid $750 million in penalties for failing to comply with drug production standards, court records show. The civil suit against the company was supported by a whistleblower as regards the production and distribution of adulterated batches of some drugs. These drugs include Kytril, Avandamet, Bactroban and Paxil CR.

1. As Published on the Paxil Birth Defects Website

2. Losing a costly legal battle with the US
federal government, SB Pharmaco Inc.
and its parent holding firm
GlaxoSmithKline (GSK) paid $750 million
in penalties for failing to comply with
drug production standards, court
records show. The civil suit against the
company was supported by a
whistleblower as regards the production
and distribution of adulterated batches
of some drugs. These drugs include
Kytril, Avandamet, Bactroban and Paxil
CR.

3. Paxil is a paroxetine hydrochloride drug which, like the
ordinary Paxil drug, serves as cure for major depressive
disorder, panic disorder, social anxiety
disorder, obsessive compulsive disorder and
premenstrual dysphoric disorder. It is also possessed of
the same Paxil side effects such as birth
defects, extreme behavioral shifts and suicidal
behavior. This formulation is meant to block the
reuptake of serotonin, which is a brain neurotransmitter
for happy emotions. Paroxetine is a part of the
antidepressant family known as selective serotonin
reuptake inhibitors.

4. SB Pharmaco did not live up to the standards placed by
authorities in the production of drugs, media reports
say. The Puerto Rico-based subsidiary breached ethical
ideals when it violated manufacturing
standards, exposing the public to the chemical hazards
of the drugs. It was reported that between the years of
2001 to 2005, the company distributed these
"adulterated and unclean" drugs. From the $750 million
payment made by the company, $150 million were
allocated as payment of fines and the remaining $600
million was spent for the claims made by the federal
government.

5. After that 2010 incident, SB
Pharmaco and GSK entered into a a
$40.8 million settlement with 37
states in 2011. The company
expressed their desire to rectify
their errors and to never allow the
same happenstance to occur again.
This measure was resorted to avoid
further litigation and more expenses
in the process. The bad report it
caused, however, created a
permanent injury for GSK as
reflected in its balance sheet.

6. The power of a Paxil lawsuit against GSK and
its corporate muscle was shown in the punitive
penalties suffered by it amounting to millions.
Nevertheless, as regards individuals exposed
to Paxil side effects, there is no value for the
injury it caused apart from for the figures
written in the compensatory claims.
Commendable as it is for GSK to settle these
cases, it fails to cover the fact that there are
real victims who have been damaged by their
product.